Talk:Serotonin–norepinephrine–dopamine reuptake inhibitor: Difference between revisions
Content deleted Content added
m moved Talk:SNDRI to Talk:Serotonin-norepinephrine-dopamine-reuptake-inhibitor: more precise name |
Tag: |
||
| (29 intermediate revisions by 17 users not shown) | |||
| Line 1: | Line 1: | ||
{{WikiProject banner shell|class=C| |
|||
{{WikiProject Medicine|importance=Mid|psychiatry=Yes|psychiatry-imp=Mid}} |
|||
{{WikiProject Pharmacology|importance=mid}} |
|||
}} |
|||
==Article deletion== |
|||
Many years ago, this article was focused on its title subject (as 99.9999% of encyclopedia articles are), noting that SNDRIs are a new frontier in psychopharmacology and that only a few are in clinical trials. Now it has transformed into an article encompassing every pharmacological class of medication. The entire purpose of having a separate article for a particular topic is to elucidate aspects that might come across as unnecessary detail when covering its broader, related/inclusive topic. If I knew nothing about psychopharmacology, I would be horribly confused after reading this. At best, this article is redundant; at worse, it is obfuscating the very subject it purports to clarify. This page, as of 2015 Dec 17, is unfit for publication and should be either revised or rewritten from scratch.[[User:Frostlark|Frostlark]] ([[User talk:Frostlark|talk]]) 17:31, 17 December 2015 (UTC) |
|||
{{oldafdfull|date= May 23, 2007 |result= '''STUBIFY''' |page= SNDRI }} |
{{oldafdfull|date= May 23, 2007 |result= '''STUBIFY''' |page= SNDRI }} |
||
This was formerly a much longer article. This longer version may be found in the history. |
This was formerly a much longer article. This longer version may be found in the history. |
||
---- |
|||
This article is complete and utter garbage. It seems like it was written entirely by one person, and that person seems very biased, ignorant and pretentious. <span style="font-size: smaller;" class="autosigned">—Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[Special:Contributions/72.200.115.120|72.200.115.120]] ([[User talk:72.200.115.120|talk]]) 07:15, 2 October 2009 (UTC)</span><!-- Template:UnsignedIP --> <!--Autosigned by SineBot--> |
|||
==References list== |
|||
{{Cot|Long list of references|bg=white}} |
|||
[http://www.ingentaconnect.com/content/ben/cnsnddt/2007/00000006/00000002 Depression (Part 1) Guest Editors: John H. Kehne and Ronald S. Duman (April 07)] |
[http://www.ingentaconnect.com/content/ben/cnsnddt/2007/00000006/00000002 Depression (Part 1) Guest Editors: John H. Kehne and Ronald S. Duman (April 07)] |
||
| Line 21: | Line 33: | ||
[http://dx.doi.org/10.1534/genetics.104.032540 Serotonin (5HT), Fluoxetine, Imipramine and Dopamine Target Distinct 5HT Receptor Signaling to Modulate Caenorhabditis elegans Egg-Laying Behavior Ji Ying Sze1 2005] |
[http://dx.doi.org/10.1534/genetics.104.032540 Serotonin (5HT), Fluoxetine, Imipramine and Dopamine Target Distinct 5HT Receptor Signaling to Modulate Caenorhabditis elegans Egg-Laying Behavior Ji Ying Sze1 2005] |
||
;Neuronal Targets of Cocaine |
|||
;Dopamine |
|||
[http://www.sciencemag.org/cgi/content/abstract/315/5816/1267 Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement (2007) J. Dalley] |
[http://www.sciencemag.org/cgi/content/abstract/315/5816/1267 Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement (2007) J. Dalley] |
||
| Line 40: | Line 53: | ||
[[Image:Biosynthese Adrenalin.png|right|400px]] |
[[Image:Biosynthese Adrenalin.png|right|400px]] |
||
;Norepinephrine |
|||
===''N''-Epinephrine=== |
|||
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17407497&query_hl=12&itool=pubmed_docsum Difference in magnitude of psychostimulant-induced extracellular norepinephrine in the ventral tegmental area contributes to discrepant prefrontal dopamine outflow Pan WH, Hsieh MC, Wu HH, Lin SK. Addict Biol. 2007 Mar;12(1):51-8.] |
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17407497&query_hl=12&itool=pubmed_docsum Difference in magnitude of psychostimulant-induced extracellular norepinephrine in the ventral tegmental area contributes to discrepant prefrontal dopamine outflow Pan WH, Hsieh MC, Wu HH, Lin SK. Addict Biol. 2007 Mar;12(1):51-8.] |
||
| Line 53: | Line 66: | ||
[http://jpet.aspetjournals.org/cgi/content/abstract/275/1/53 Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys (95 Spealman)] |
[http://jpet.aspetjournals.org/cgi/content/abstract/275/1/53 Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys (95 Spealman)] |
||
;Serotonin |
|||
[http://dx.doi.org/10.1124/jpet.106.108324 Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys. (2007)] |
[http://dx.doi.org/10.1124/jpet.106.108324 Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys. (2007)] |
||
| Line 68: | Line 81: | ||
[http://dx.doi.org/10.1016/j.yebeh.2005.07.014 The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Ronald B.P. Jobe 2005] |
[http://dx.doi.org/10.1016/j.yebeh.2005.07.014 The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Ronald B.P. Jobe 2005] |
||
;'''σ'''–Receptors |
|||
[http://dx.doi.org/10.1016/S0014-2999(03)01723-0 σ Receptors: potential medications development target for anti-cocaine agents (03) Matsumoto] |
[http://dx.doi.org/10.1016/S0014-2999(03)01723-0 σ Receptors: potential medications development target for anti-cocaine agents (03) Matsumoto] |
||
[http://dx.doi.org/10.1016/S0028-3908(02)00056-4 Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides R. Matsumoto, K. McCracken (2002).] |
[http://dx.doi.org/10.1016/S0028-3908(02)00056-4 Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides R. Matsumoto, K. McCracken (2002).] |
||
;Cholinergic |
|||
[http://jpet.aspetjournals.org/cgi/content/abstract/289/3/1229 Pharmacological Characterization of Nicotine's Interaction with Cocaine and Cocaine Analogs J Pharmacol Exp Ther 1999 289: 1229-1236.] |
[http://jpet.aspetjournals.org/cgi/content/abstract/289/3/1229 Pharmacological Characterization of Nicotine's Interaction with Cocaine and Cocaine Analogs J Pharmacol Exp Ther 1999 289: 1229-1236.] |
||
| Line 80: | Line 93: | ||
[http://dx.doi.org/10.1007/s002130050197 Ritz* Cocaine-induced convulsions: pharmacological antagonism at serotonergic, muscarinic and sigma receptors '97] |
[http://dx.doi.org/10.1007/s002130050197 Ritz* Cocaine-induced convulsions: pharmacological antagonism at serotonergic, muscarinic and sigma receptors '97] |
||
;Na+ Channels |
|||
[http://www3.interscience.wiley.com/cgi-bin/abstract/112098312/ABSTRACT In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. (2005)] |
[http://www3.interscience.wiley.com/cgi-bin/abstract/112098312/ABSTRACT In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. (2005)] |
||
[http://www.springerlink.com/content/w98a86ta5f754d2j/ On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys. (2000)] |
[http://www.springerlink.com/content/w98a86ta5f754d2j/ On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys. (2000)] |
||
;Ionotropic Glutamate Receptors |
|||
[http://www.annalsnyas.org/cgi/content/full/1074/1/403 AMPA and NMDA Receptors in P2 Fractions of Cocaine and Cocaine–Prazosin-Treated Rats August 2006] |
[http://www.annalsnyas.org/cgi/content/full/1074/1/403 AMPA and NMDA Receptors in P2 Fractions of Cocaine and Cocaine–Prazosin-Treated Rats August 2006] |
||
| Line 91: | Line 104: | ||
[http://www3.interscience.wiley.com/cgi-bin/abstract/98515625/ABSTRACT Repeated cocaine administration differentially affects NMDA receptor subunit (NR1, NR2A-C) mRNAs in rat brain Mika Yamaguchi 1 2, Toshihito Suzuki 1 2 *, Shuzo Abe 2, Takafumi Hori 2, Hirofumi Kurita 2, Takashi Asada 2, Nobuo Okado 3, Heii Arai '02] |
[http://www3.interscience.wiley.com/cgi-bin/abstract/98515625/ABSTRACT Repeated cocaine administration differentially affects NMDA receptor subunit (NR1, NR2A-C) mRNAs in rat brain Mika Yamaguchi 1 2, Toshihito Suzuki 1 2 *, Shuzo Abe 2, Takafumi Hori 2, Hirofumi Kurita 2, Takashi Asada 2, Nobuo Okado 3, Heii Arai '02] |
||
{{cob}} |
|||
== Article re-written == |
|||
I've re-written some of the article to remove irrelevant information and outdated clinical candidates. I've shrunk the size of the article significantly, however I think that perhaps adding more information about the three relevant neurotransmitters roles in depression would be useful. It also needs more citations. [[User:Comrinec|Comrinec]] ([[User talk:Comrinec|talk]]) 16:40, 6 June 2010 (UTC) |
|||
==Still too large article for such a small class of substances which includes especially cocaine== |
|||
Most of the substances mentioned in the article are not triple "Serotonin-norepinephrine-dopamine reuptake inhibitors" "SNDRI". The article makes a long review of many other classes which are not at all "SNDRI". It speaks about MAOI, SSRI, SNRI which all of them are not at all "SNDRI" and have no relevance to the item. The main and most known "SNDRI" is cocaine, which is a psychostimulant abuse substance and recreational drug, which causes a high and dangerous craving, compulsive drug seeking, associated with the activation of specific reward structures in the brain, with daily or binges abuse, often dependence, intoxications with potential agitation, anxiety. paranoia or agressiveness, discontinuation syndromes often with severe depression. The presence of SSRi, SNRI, and other antidepressive medications which are not "SNDRI", and are not abusable substance, only is producing confusion among the readers, confusion between pharmacological treatment and substance abuse.[[User:Ewan2|Ewan2]] ([[User talk:Ewan2|talk]]) 21:43, 4 July 2014 (UTC) |
|||
==Dimebon== |
|||
The part about magic bullet pharmaceutical drugs which gives dimebon as an example of an expecially efficient drug is contrary to new research about this substance and is also contradictory to the Wikipedia article on dimebon. <!-- Template:Unsigned IP --><small class="autosigned">— Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[Special:Contributions/217.209.169.236|217.209.169.236]] ([[User talk:217.209.169.236#top|talk]]) 12:56, 14 January 2017 (UTC)</small> <!--Autosigned by SineBot--> |
|||
:I've fixed this. [[User:Seppi333|'''<span style="color:#32CD32;">Seppi</span>''<span style="color:Black;">333</span>''''']] ([[User Talk:Seppi333|Insert '''2¢''']]) 22:52, 14 January 2017 (UTC) |
|||
Latest revision as of 22:56, 30 January 2024
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
| ||||||||||||||||||||||||
Article deletion
[edit]Many years ago, this article was focused on its title subject (as 99.9999% of encyclopedia articles are), noting that SNDRIs are a new frontier in psychopharmacology and that only a few are in clinical trials. Now it has transformed into an article encompassing every pharmacological class of medication. The entire purpose of having a separate article for a particular topic is to elucidate aspects that might come across as unnecessary detail when covering its broader, related/inclusive topic. If I knew nothing about psychopharmacology, I would be horribly confused after reading this. At best, this article is redundant; at worse, it is obfuscating the very subject it purports to clarify. This page, as of 2015 Dec 17, is unfit for publication and should be either revised or rewritten from scratch.Frostlark (talk) 17:31, 17 December 2015 (UTC)
 | This article was nominated for deletion on May 23, 2007. The result of the discussion was STUBIFY. |
This was formerly a much longer article. This longer version may be found in the history.
This article is complete and utter garbage. It seems like it was written entirely by one person, and that person seems very biased, ignorant and pretentious. —Preceding unsigned comment added by 72.200.115.120 (talk) 07:15, 2 October 2009 (UTC)
References list
[edit]
Article re-written
[edit]I've re-written some of the article to remove irrelevant information and outdated clinical candidates. I've shrunk the size of the article significantly, however I think that perhaps adding more information about the three relevant neurotransmitters roles in depression would be useful. It also needs more citations. Comrinec (talk) 16:40, 6 June 2010 (UTC)
Still too large article for such a small class of substances which includes especially cocaine
[edit]Most of the substances mentioned in the article are not triple "Serotonin-norepinephrine-dopamine reuptake inhibitors" "SNDRI". The article makes a long review of many other classes which are not at all "SNDRI". It speaks about MAOI, SSRI, SNRI which all of them are not at all "SNDRI" and have no relevance to the item. The main and most known "SNDRI" is cocaine, which is a psychostimulant abuse substance and recreational drug, which causes a high and dangerous craving, compulsive drug seeking, associated with the activation of specific reward structures in the brain, with daily or binges abuse, often dependence, intoxications with potential agitation, anxiety. paranoia or agressiveness, discontinuation syndromes often with severe depression. The presence of SSRi, SNRI, and other antidepressive medications which are not "SNDRI", and are not abusable substance, only is producing confusion among the readers, confusion between pharmacological treatment and substance abuse.Ewan2 (talk) 21:43, 4 July 2014 (UTC)
Dimebon
[edit]The part about magic bullet pharmaceutical drugs which gives dimebon as an example of an expecially efficient drug is contrary to new research about this substance and is also contradictory to the Wikipedia article on dimebon. — Preceding unsigned comment added by 217.209.169.236 (talk) 12:56, 14 January 2017 (UTC)
- I've fixed this. Seppi333 (Insert 2¢) 22:52, 14 January 2017 (UTC)